SCHEMBL6319769

SCHEMBL6319769

Cc1cc(C(=O)O)[nH]c1C=C1C(=O)Nc2cccc(-c3cccc(Cl)c3)c21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.50
EGFR P00533 2/20 0.46
ERBB2 P04626 1/20 0.46
RET P07949 6/20 0.46
ALK Q9UM73 5/20 0.46
FGFR1 P11362 3/20 0.46
FLT1 P17948 3/20 0.46
FLT3 P36888 3/20 0.46
PDGFRB P09619 3/20 0.46
CSF1R P07333 2/20 0.46
SRC P12931 2/20 0.46
FGFR3 P22607 2/20 0.46
MAPK1 P28482 2/20 0.46
FLT4 P35916 2/20 0.46
PDPK1 O15530 2/20 0.46
ABL1 P00519 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319763 1.00 KDR (0.50) KDREGFRERBB2RETALK
SCHEMBL6321190 0.91 KDR (0.51) KDREGFRERBB2RETALK
SCHEMBL6321187 0.91 KDR (0.51) KDREGFRERBB2RETALK
SCHEMBL6322309 0.88 KDR (0.50) KDREGFRERBB2RETALK
SCHEMBL6322009 0.88 KDR (0.50) KDREGFRERBB2RETALK
SCHEMBL6321545 0.88 KDR (0.50) KDREGFRERBB2RETALK
SCHEMBL6322011 0.88 KDR (0.50) KDREGFRERBB2RETALK
SCHEMBL6321965 0.87 RET (0.62) KDRRETALKFGFR1FLT1
SCHEMBL6321958 0.87 RET (0.62) KDRRETALKFGFR1FLT1
SCHEMBL6319334 0.87 KDR (0.51) KDREGFRRETALKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885EGFR 367/4885ERBB2 28/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885EGFR 367/4885ERBB2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.